Compare iShares 3 7 Year Treasury Bond ETF (IEI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 3 7 Year Treasury Bond ETF vs BIO-TECHNE Corp — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $113.57 (market cap $16.76B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: iShares 3 7 Year Treasury Bond ETF is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while iShares 3 7 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares 3 7 Year Treasury Bond ETF for 43 Days and BIO-TECHNE Corp for 63 Days on average.
| IEI | TECH | |
|---|---|---|
Market Cap | $16.76B | $11.37B |
Volume | 3,727,970 | 3,153,511 |
Sector | Fixed Income | Health |
52-Week High | $120.72 | $72.61 |
52-Week Low | $113.17 | $43.31 |
Typical Hold Time | 43 Days | 63 Days |
Enterprise Value | — | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEI trades at $113.38, showing minimal daily movement with a 0.04% gain amid a bearish technical backdrop. The stock faces selling pressure across multiple indicators, with moving averages and oscillators signaling caution. Recent dividend payments of $0.37-0.38 per share provide income support, but financial ratios remain undisclosed in current data. Bond market volatility and rising Treasury yields create a challenging environment for income-focused investments.
The outlook remains cautious given the bearish technical signals and broader market headwinds from rising interest rates. Income investors may find dividend payments attractive, but the lack of fundamental data and negative technical momentum suggests limited near-term upside potential. Key risks include interest rate sensitivity and broader fixed income market volatility affecting investor sentiment.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
